The DF/HCC Program in Biostatistics and Computational Biology fosters a broad range of research into statistical, computational and mathematical questions that arise in cancer investigations. Its members are engaged in trans-disciplinary and inter-programmatic projects across population, clinical and basic cancer research. Biostatistics has been a Program since the formation of DF/HCC and was rated as outstanding at the time ofthe last CCSG renewal. The name ofthe Program was changed to Biostatistics and Computational Biology in 2010, with the support ofthe EAB, in order to recognize the strong contribution of computational biologists. This Program is led by G. Parmigiani and R. Betensky and has 45 members from all member institutions. Members are affiliated with two departments at HSPH (Biostatistics and Epidemiology) and six departments at HMS (Biological Chemistry and Molecular Pharmacology, Population Medicine, Medicine, Health Care Policy, Pediatrics and Radiation Oncology). The Program has two Specific Aims: 1) to develop and disseminate new tools in statistical science and computational biology that respond to emerging areas of cancer research;and 2) to develop software for the implementation of these tools. The Biostatistics and Computational Biology Program continues to be highly successful in securing external funding. In 2009, peer-reviewed grant funding attributed to the Program was $14.4 million in total costs, of which nearly $7 million was from NCI (49%) and $7.4 million was from other peer-reviewed sponsors. Attesting to the productivity and interactivity ofthe Program are the 1,666 publications authored by members during the project period, of which 4.2% were intra-programmatic, 44% were inter-programmatic and 33% were inter-institutional collaborations.
The DF/HCC Program in Biostatistics and Computational Biology fosters research into the mathematical, computational, and statistical questions that arise in cancer research. It supports methodological as well as inter-disciplinary and inter-programmatic research across population, clinical and basic cancer research.
|Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :|
|Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8|
|Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52|
|Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8|
|Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504|
|Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96|
|McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534|
|Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201|
|Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46|
|Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381|
Showing the most recent 10 out of 303 publications